^aA multicenter, randomized, double-blind, placebo-controlled study of 101 adult, mild-to-moderate asthma patients that evaluated the efficacy and safety of AZMACORT 300 mcg BID daily for 6 weeks. The primary measures of efficacy were the mean changes from baseline to 6 weeks in FEV, and 24-hour albuterol use. A secondary measure was the change from baseline to 6 weeks in daytime and nighttime symptoms.

^bThe 300-mcg dose was a more precise quantitation of the total dose of active ingredient than the 400-mcg dose.³

• AZMACORT achieved significantly greater reduction in both chronic daytime and nighttime symptoms vs placebo²
• Adverse events were similar for both groups, with 2 exceptions²
  • Lung-related symptoms (eg, increased cough, asthma, dyspnea) occurred more frequently in the placebo group
  • Pharyngitis occurred more frequently in patients taking AZMACORT

AZMACORT Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. AZMACORT is also indicated for asthma patients who require systemic corticosteroid administration, where adding AZMACORT may reduce or eliminate the need for the systemic corticosteroids.

AZMACORT is NOT indicated for the relief of acute bronchospasm.